S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
S&P 500   3,900.79 (-0.58%)
DOW   31,253.13 (-0.75%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
NASDAQ:GLPG

Galapagos (GLPG) Stock Forecast, Price & News

$56.95
+1.36 (+2.45%)
(As of 05/19/2022 04:00 PM ET)
Add
Compare
Today's Range
$55.96
$57.12
50-Day Range
$55.59
$71.59
52-Week Range
$46.41
$81.12
Volume
252,647 shs
Average Volume
376,065 shs
Market Capitalization
$3.74 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.49
30 days | 90 days | 365 days | Advanced Chart
Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for Galapagos and its competitors with MarketBeat's FREE daily newsletter.

Galapagos logo

About Galapagos

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GLPG
Employees
1,309
Year Founded
N/A

Sales & Book Value

Annual Sales
$573.66 million
Book Value
$45.24 per share

Profitability

Net Income
$-122.13 million
Pretax Margin
-24.83%

Debt

Price-To-Earnings

Miscellaneous

Free Float
63,738,000
Market Cap
$3.74 billion
Optionable
Optionable

Company Calendar

Today
5/19/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.35 out of 5 stars

Medical Sector

1116th out of 1,418 stocks

Pharmaceutical Preparations Industry

555th out of 677 stocks

Analyst Opinion: 2.2Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Galapagos (NASDAQ:GLPG) Frequently Asked Questions

Is Galapagos a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Galapagos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLPG, but not buy additional shares or sell existing shares.
View analyst ratings for Galapagos
or view top-rated stocks.

When is Galapagos' next earnings date?

Galapagos is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Galapagos
.

What price target have analysts set for GLPG?

9 Wall Street analysts have issued 1-year price objectives for Galapagos' stock. Their forecasts range from $50.00 to $80.00. On average, they expect Galapagos' share price to reach $65.97 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price.
View analysts' price targets for Galapagos
or view top-rated stocks among Wall Street analysts.

Who are Galapagos' key executives?
Galapagos' management team includes the following people:
  • Mr. Bart Filius M.B.A., MBA, Pres, COO & Member of Management Board (Age 52, Pay $851.07k)
  • Dr. Andre Hoekema, Chief Bus. Officer & Member of Management Board (Age 65, Pay $599.66k)
  • Dr. Walid Abi-Saab, Chief Medical Officer & Member of Management Board (Age 57, Pay $708.34k)
  • Mr. Michele Manto M.B.A., Chief Commercial Officer & Member of Management Board
  • Dr. Paulus A. Stoffels M.D., Ph.D., Chief Exec. Officer (Age 60)
  • Ms. Elizabeth Goodwin, VP of Investor Relations
  • Ms. Sofie Van Gijsel, Head of Investor Relations
  • Marieke Vermeersch, Head of Corp. Communication
  • John Montana, Managing Director of Argenta
  • Ms. Chantal Tasset, Head of Devel.
What is Onno van de Stolpe's approval rating as Galapagos' CEO?

6 employees have rated Galapagos CEO Onno van de Stolpe on Glassdoor.com. Onno van de Stolpe has an approval rating of 100% among Galapagos' employees. This puts Onno van de Stolpe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

When did Galapagos IPO?

(GLPG) raised $161 million in an initial public offering on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company served as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is Galapagos' stock symbol?

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Who are Galapagos' major shareholders?

Galapagos' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.79%), Great Point Partners LLC (0.55%), JPMorgan Chase & Co. (0.46%), Greenlight Capital Inc. (0.24%), Renaissance Technologies LLC (0.13%) and Goldman Sachs Group Inc. (0.10%).

Which institutional investors are selling Galapagos stock?

GLPG stock was sold by a variety of institutional investors in the last quarter, including Silverarc Capital Management LLC, Monaco Asset Management SAM, UBS Group AG, HAP Trading LLC, Greenlight Capital Inc., Goldman Sachs Group Inc., Quantbot Technologies LP, and Citigroup Inc..

Which institutional investors are buying Galapagos stock?

GLPG stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Great Point Partners LLC, Endurant Capital Management LP, Arrowstreet Capital Limited Partnership, Jane Street Group LLC, Renaissance Technologies LLC, Simplex Trading LLC, and Group One Trading L.P..

How do I buy shares of Galapagos?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galapagos' stock price today?

One share of GLPG stock can currently be purchased for approximately $56.95.

How much money does Galapagos make?

Galapagos has a market capitalization of $3.74 billion and generates $573.66 million in revenue each year.

How many employees does Galapagos have?

Galapagos employs 1,309 workers across the globe.

What is Galapagos' official website?

The official website for Galapagos is www.glpg.com.

How can I contact Galapagos?

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at (321) 534-2900, via email at [email protected], or via fax at 321-534-2901.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.